Citizens Financial Group Inc. RI Has $294,000 Stock Holdings in Agilent Technologies, Inc. $A

Citizens Financial Group Inc. RI raised its position in Agilent Technologies, Inc. (NYSE:A) by 25.3% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 2,493 shares of the medical research company’s stock after acquiring an additional 503 shares during the period. Citizens Financial Group Inc. RI’s holdings in Agilent Technologies were worth $294,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in A. Resona Asset Management Co. Ltd. grew its holdings in shares of Agilent Technologies by 6.2% in the 2nd quarter. Resona Asset Management Co. Ltd. now owns 98,400 shares of the medical research company’s stock valued at $11,631,000 after acquiring an additional 5,767 shares in the last quarter. TrueMark Investments LLC bought a new stake in Agilent Technologies during the second quarter worth about $1,999,000. Fenimore Asset Management Inc boosted its position in Agilent Technologies by 2.7% during the second quarter. Fenimore Asset Management Inc now owns 180,880 shares of the medical research company’s stock valued at $21,346,000 after purchasing an additional 4,823 shares during the last quarter. Nuance Investments LLC boosted its position in Agilent Technologies by 13.5% during the second quarter. Nuance Investments LLC now owns 80,698 shares of the medical research company’s stock valued at $9,523,000 after purchasing an additional 9,628 shares during the last quarter. Finally, Carmel Capital Partners LLC grew its stake in Agilent Technologies by 32.3% in the second quarter. Carmel Capital Partners LLC now owns 10,928 shares of the medical research company’s stock valued at $1,290,000 after purchasing an additional 2,667 shares in the last quarter. 87.41% of the stock is owned by institutional investors.

Agilent Technologies Stock Performance

A opened at $144.62 on Thursday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. The business has a fifty day simple moving average of $138.72 and a 200 day simple moving average of $124.66. Agilent Technologies, Inc. has a 1 year low of $96.43 and a 1 year high of $153.84. The company has a market capitalization of $41.00 billion, a PE ratio of 33.95, a price-to-earnings-growth ratio of 4.67 and a beta of 1.29.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, hitting the consensus estimate of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.67 billion. During the same quarter last year, the business earned $1.32 EPS. The company’s quarterly revenue was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Research analysts expect that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 6th will be paid a $0.255 dividend. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.25. The ex-dividend date is Tuesday, January 6th. This represents a $1.02 annualized dividend and a yield of 0.7%. Agilent Technologies’s dividend payout ratio is presently 23.24%.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 12,490 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $150.00, for a total value of $1,873,500.00. Following the completion of the sale, the chief executive officer owned 33,448 shares of the company’s stock, valued at $5,017,200. The trade was a 27.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.26% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Evercore ISI upped their price objective on Agilent Technologies from $128.00 to $140.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 7th. Robert W. Baird boosted their target price on shares of Agilent Technologies from $141.00 to $142.00 and gave the stock an “outperform” rating in a report on Thursday, August 28th. UBS Group raised shares of Agilent Technologies from a “neutral” rating to a “buy” rating and upped their price target for the stock from $130.00 to $170.00 in a research report on Wednesday, October 8th. Barclays lifted their price objective on shares of Agilent Technologies from $125.00 to $150.00 and gave the company an “equal weight” rating in a research report on Thursday, October 2nd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Agilent Technologies in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $149.62.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.